COVID-19, Frailty, Sarcopenia
Conditions
Brief summary
Frailty is associated with higher rates of morbidity, mortality, and failure to rescue after major surgical procedures. Sarcopenia is degenerative loss of skeletal muscle mass and strength. It is a key component of physical frailty and is associated with poorer post-surgical outcomes due to decreased patient strength and vitality.
Detailed description
This study seeks to examine whether the (COVID-19) pandemic, an ongoing global health crisis that was declared a national emergency by the US Federal Government on March 13, 2020, has exacerbated both frailty and sarcopenia in a population of liver transplant candidates.
Interventions
BEHAVIORALCOVID Patients who Underwent pre-transplant frailty assessment (PFA) at MDMC
This is a single-center, retrospective study that uses de-identified, anonymized patient data. Data from 369 liver transplant candidates who underwent pre-transplant frailty assessments at the Liver Institute at Methodist Dallas from April 1, 2018 to February 28, 2022. The study data will be divided into cohorts: pre-COVID and COVID. Specifically, the pre-COVID period will consist of the dates between April 1st, 2018 and March 12, 2020, while the COVID period will consist of the dates between March 13, 2020 and February 28th, 2022.
Sponsors
Methodist Health System
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age 18 years and older Underwent pre-transplant frailty assessment (PFA) at MDMC
Exclusion criteria
* Not a patient at Liver Institute at Methodist Dallas
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To determine the impact of the COVID-19 pandemic on the prevalence of sarcopenia | 2 years | To determine the impact of the COVID-19 pandemic on the prevalence of sarcopenia and frailty in patients undergoing liver transplant evaluation at Methodist Dallas Medical Center |
| To determine the impact of the COVID-19 pandemic on the incidence of sarcopenia | 2 years | To determine the impact of the COVID-19 pandemic on the incidence of sarcopenia and frailty in patients undergoing liver transplant evaluation at Methodist Dallas Medical Center |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in number of comorbidities between pre- and during/post-pandemic periods | 1 year | Changes in number of comorbidities between pre- and during/post-pandemic periods |
| Changes in type of comorbidities between pre- and during/post-pandemic periods | 1 year | Changes in type of comorbidities between pre- and during/post-pandemic periods |
| Changes in severity of comorbidities between pre- and during/post-pandemic periods | 1 year | Changes in severity of comorbidities between pre- and during/post-pandemic periods |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORParvez Mantry, MD
Methodist Health System
Outcome results
None listed